EICHOR
● Recruiting
A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors
Condition: Advanced Solid Tumor · Sponsor: Broadenbio Ltd., Co.
About this study
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced solid tumors. This study has two phase: dose escalation phase and expansion phase.
This description comes directly from the study's public registry record.
Talk to the study team
Qi Wang, PhD · +86-15311443674 · qi.wang@broadenbio.com
Always discuss trial participation with your own doctor first.
Locations (2)
| Nanfang Hospital | Guangzhou, Guangdong, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06258408